Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression


- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) -

Read more from the original source:
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

Related Posts